BeiGene finalizes a $1.3B Agreement with Ensem for the CDK2 Inhibitor

Cambridge, MA, November 21, 2023 (MSN) -- BeiGene secures global licensing for Ensem Therapeutics' oral cyclin-dependent kinase-2 (CDK2) inhibitor aimed at breast cancer treatment. The deal involves an undisclosed upfront payment to Ensem, with potential milestone payments totaling up to $1.33 billion, along with tiered royalties.

Read full article here.